Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on January 30, 2023. The report discloses the appointment of Timothy Keutzer as Chief Operating Officer, effective February 1, 2023. Mr. Keutzer previously served as the Company's Chief Development Officer since June 2019.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Compensation
In connection with the appointment, the Company entered into a Second Amendment to Mr. Keutzer's employment agreement. Key terms include:
- Base Salary: Annual base salary set at $459,000.
- Annual Bonus: Target bonus maintained at up to 40% of base salary, contingent on performance objectives.
- Equity Grant: Restricted Stock Units (RSUs) with an aggregate fair market value of $500,000, vesting in four equal annual installments starting on the first anniversary of the Effective Date.
Outlook, Risks, and Contingencies
The filing details severance provisions contingent on termination without Cause or for Good Reason:
- Standard Termination: Nine months of base salary, pro-rated target bonus, and continued health insurance coverage for up to 12 months.
- Change of Control Termination: If termination occurs within 90 days prior to or one year following a Change of Control, Mr. Keutzer is entitled to a lump sum equal to 12 months of base salary plus the target bonus, full acceleration of unvested equity awards, and continued health insurance for up to 12 months.
Payments are subject to the execution of a release satisfactory to the Company.
Investor Verification Checklist
- Verify the exact number of RSUs granted by dividing $500,000 by the closing stock price on February 1, 2023.
- Review the full text of the Second Amendment to the employment agreement when filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2023.
- Confirm the definitions of "Cause" and "Good Reason" in the Original Agreement to understand severance triggers.
- Monitor future filings for any impact of this executive change on the Company's operational strategy or pipeline development.